A Phase 3 interventional study of Setmelanotide in Bardet-Biedl Syndrome, POMC Deficiency Obesity and PCSK1 Deficiency Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 6 sites in 4 countries. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2024-11-27.
Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.
Among the 16 studies testing setmelanotide in Obesity, this one is the 14th largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 3, and was the 11th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
By country, each count listing its studies:
setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 2 Years to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 7
First in 2012; this study’s year is marked. 2 started in 2022.
This study's enrollment of 12 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 34 across the 16 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 2 most frequent:
Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
19 studies in Obesity by Rhythm Pharmaceuticals, Inc.: none open now, 2 under way, none of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 19 studies in Obesity by Rhythm Pharmaceuticals, Inc., this one is the 15th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2022, is one of 6 in phase 3, and was the 13th registered.
Rhythm Pharmaceuticals, Inc.’s Obesity studies by the year they started, since 2012.
1 of the studies testing setmelanotide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496463Massachusetts General HospitalSetmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing setmelanotide in Obesity, from their registry updates:
Among Rhythm Pharmaceuticals, Inc.’s 19 in Obesity:
This tab as a report to print or save as PDF → With an account.
This is a phase 3 open-label, clinical study to evaluate the efficacy, safety and tolerability of setmelanotide over 1 year of treatment, in pediatric participants aged 2 to \<6 years with obesity due to either biallelic variants of the pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) genes or Bardet-Biedl Syndrome (BBS).
Pediatric participants aged 2 to \<6 years with obesity due to either biallelic variants of the POMC, PCSK1 or LEPR genes or BBS will be enrolled into this phase 3 open-label clinical trial at one of approximately 8 clinical centers in North America, Europe, or Australia. All participants will be assigned to receive setmelanotide via daily subcutaneous (SC) injection for 1 year.
Key Inclusion Criteria:
Participants must have obesity due to either:
Key Exclusion Criteria
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with POMC)/PCSK1/LEPR biallelic mutations collectively referred to as PPL received setmelanotide at a dose of 0.5 milligrams (mg) per day (QD) via SC injection for 52 weeks. The dose was escalated by increments of 0.5 mg every 2 weeks, if tolerated, at the dose escalation visits (Weeks 2, 4, and 6) to a maximum dose of 0.5 to 2.0 mg QD with the maximum dose based on body weight. Following the last dose in this study, participants who were considered likely to benefit from continued setmelanotide treatment and who had completed this trial could be eligible to enter an open-label long-term extension (LTE) trial with setmelanotide.
Drug: Setmelanotide
Participants with BBS received setmelanotide at a dose of 0.5 mg QD via SC injection for 52 weeks. The dose was escalated by increments of 0.5 mg every 2 weeks, if tolerated, at the dose escalation visits (Weeks 2, 4, and 6) to a maximum dose of 0.5 to 2.0 mg QD with the maximum dose based on body weight. Following the last dose in this study, participants who were considered likely to benefit from continued setmelanotide treatment and who had completed this trial could be eligible to enter an open-label long-term extension (LTE) trial with setmelanotide.
Drug: Setmelanotide
SC injection once daily.
Also known as: IMCIVREE
Percentage of Participants With Greater Than or Equal to (≥) 0.2 Reduction of BMI Z-Score From Baseline to Week 52
A "responder" was defined as a decrease from baseline to 52 weeks in the participant's BMI z-score of ≥0.2. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-scores were based on the World Health Organization's Child Growth Standards 2007 and indicated the number of standard deviations away from the mean. A Z-score of 0 was equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score (\< 0) indicated a reduction in BMI from Baseline whereas an increase of BMI-Z score (\> 0) indicated an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.
Time frame: Baseline up to Week 52
Mean Percent Change From Baseline in BMI
Mean percent change from baseline to Week 52 in BMI was reported. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. Baseline was defined as the most recent measurement prior to the first administration of study drug.
Time frame: Baseline, Week 52
Mean Absolute Change From Baseline in BMI Z-score
Mean absolute change from baseline to Week 52 in BMI Z-score was reported. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-scores were based on the World Health Organization's Child Growth Standards 2007 and indicated the number of standard deviations away from the mean. A Z-score of 0 was equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score (\< 0) indicated a reduction in BMI from Baseline whereas an increase of BMI-Z score (\> 0) indicated an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.
Time frame: Baseline, Week 52
Mean Change From Baseline in Percent of the 95th Percentile of BMI
Mean change from baseline to Week 52 in percent of the 95th percentile of BMI was reported. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. BMI Percentile-scores are measures of relative weight adjusted for child age and gender. The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population. Baseline was defined as the most recent measurement prior to the first administration of study drug.
Time frame: Baseline, Week 52
Mean Change From Baseline in Bone Age
Mean change from baseline to Week 52 in bone age was reported. A standard bone age measurement (of the hand/wrist area) was obtained at the beginning and the end of the trial to monitor for growth related safety concerns. Baseline was defined as the most recent measurement prior to the first administration of study drug.
Time frame: Baseline, Week 52
Number of Participants With Shift From Baseline in Ages & Stages Questionnaires, Third Edition (ASQ-3)
ASQ-3: developmental screening questionnaire that consists of 5 areas: communication, gross motor, fine motor, problem solving, and personal-social. Each area has 6 questions scored as Yes=10 points, Sometimes=5 points, and Not yet=0 points. A child can score between 0-60 points for each area with total score range: 0 to 300; higher scores are indicative of improvement. Total area score is then compared to age-adjusted standardized score cutoff (determined by developers of tool) which indicate whether child's development appears to be on schedule according to these categories: Below=Total analysis score (TAS) is below cutoff. Further assessment with professional may be needed; Monitor=TAS is close to cutoff. Provide learning activities and monitor; Above= TAS is above cutoff, and child's development appears to be on schedule. Shift from baseline for each developmental area of assessment according to these 3 outcome categories was reported. Total score was not applicable.
Time frame: From Baseline to Week 52
Change From Baseline in Body Weight
Change from baseline to Week 52 in body weight was reported.
Time frame: Baseline, Week 52
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE was defined as any AE that started or worsened in intensity on or after the date of the first administration of study drug.
Time frame: From first dose of study drug up to Week 56
Number of Participants With TEAEs Graded by Severity
A TEAE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE was defined as any AE that started or worsened in intensity on or after the date of the first administration of study drug. TEAEs were graded according to Common Terminology Criteria for Adverse Events (CTCAE) criteria. Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life Threatening; Grade 5- Death related to AE.
Time frame: From first dose of study drug up to Week 56
| Milestone | Setmelanotide: PPL Group | Setmelanotide: BBS Group |
|---|---|---|
| Started | 7 | 5 |
| Completed | 6 | 5 |
| Not completed | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
A "responder" was defined as a decrease from baseline to 52 weeks in the participant's BMI z-score of ≥0.2. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-scores were based on the World Health Organization's Child Growth Standards 2007 and indicated the number of standard deviations away from the mean. A Z-score of 0 was equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score (\< 0) indicated a reduction in BMI from Baseline whereas an increase of BMI-Z score (\> 0) indicated an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.
| percentage of participants | Setmelanotide: PPL Group | Setmelanotide: BBS Group |
|---|---|---|
| Percentage of Participants With Greater Than or Equal to (≥) 0.2 Reduction of BMI Z-Score From Baseline to Week 52 | 85.7 (54.1 to 100) | 80.0 (28.4 to 99.5) |
Mean percent change from baseline to Week 52 in BMI was reported. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. Baseline was defined as the most recent measurement prior to the first administration of study drug.
| percent change | Setmelanotide: PPL Group | Setmelanotide: BBS Group |
|---|---|---|
| Mean Percent Change From Baseline in BMI | -25.597 ± 11.4911 | -9.719 ± 8.8383 |
Mean absolute change from baseline to Week 52 in BMI Z-score was reported. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-scores were based on the World Health Organization's Child Growth Standards 2007 and indicated the number of standard deviations away from the mean. A Z-score of 0 was equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score (\< 0) indicated a reduction in BMI from Baseline whereas an increase of BMI-Z score (\> 0) indicated an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.
| Z-score | Setmelanotide: PPL Group | Setmelanotide: BBS Group |
|---|---|---|
| Mean Absolute Change From Baseline in BMI Z-score | -5.185 ± 1.8585 | -1.331 ± 1.2295 |
Mean change from baseline to Week 52 in percent of the 95th percentile of BMI was reported. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. BMI Percentile-scores are measures of relative weight adjusted for child age and gender. The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population. Baseline was defined as the most recent measurement prior to the first administration of study drug.
| percentage relative to 95th percentile | Setmelanotide: PPL Group | Setmelanotide: BBS Group |
|---|---|---|
| Mean Change From Baseline in Percent of the 95th Percentile of BMI | -47.595 ± 17.3280 | -14.462 ± 13.8571 |
Mean change from baseline to Week 52 in bone age was reported. A standard bone age measurement (of the hand/wrist area) was obtained at the beginning and the end of the trial to monitor for growth related safety concerns. Baseline was defined as the most recent measurement prior to the first administration of study drug.
| years | Setmelanotide: PPL Group | Setmelanotide: BBS Group |
|---|---|---|
| Mean Change From Baseline in Bone Age | 1.020 ± 1.0733 | 0.700 ± 0.8367 |
ASQ-3: developmental screening questionnaire that consists of 5 areas: communication, gross motor, fine motor, problem solving, and personal-social. Each area has 6 questions scored as Yes=10 points, Sometimes=5 points, and Not yet=0 points. A child can score between 0-60 points for each area with total score range: 0 to 300; higher scores are indicative of improvement. Total area score is then compared to age-adjusted standardized score cutoff (determined by developers of tool) which indicate whether child's development appears to be on schedule according to these categories: Below=Total analysis score (TAS) is below cutoff. Further assessment with professional may be needed; Monitor=TAS is close to cutoff. Provide learning activities and monitor; Above= TAS is above cutoff, and child's development appears to be on schedule. Shift from baseline for each developmental area of assessment according to these 3 outcome categories was reported. Total score was not applicable.
| Participants | Setmelanotide: PPL Group | Setmelanotide: BBS Group |
|---|---|---|
| Communication — Baseline (Above): Week 52 (Above) | 5 | 2 |
| Communication — Baseline (Above): Week 52 (Monitor) | 0 | 0 |
| Communication — Baseline (Above): Week 52 (Below) | 0 | 0 |
| Communication — Baseline (Monitor): Week 52 (Above) | 0 | 0 |
| Communication — Baseline (Monitor): Week 52 (Monitor) | 0 | 1 |
| Communication — Baseline (Monitor): Week 52 (Below) | 0 | 0 |
| Communication — Baseline (Below): Week 52 (Above) | 0 | 0 |
| Communication — Baseline (Below): Week 52 (Monitor) | 0 | 0 |
| Communication — Baseline (Below): Week 52 (Below) | 1 | 2 |
| Fine Motor — Baseline (Above): Week 52 (Above) | 4 | 2 |
| Fine Motor — Baseline (Above): Week 52 (Monitor) | 0 | 0 |
| Fine Motor — Baseline (Above): Week 52 (Below) | 0 | 0 |
| Fine Motor — Baseline (Monitor): Week 52 (Above) | 0 | 1 |
| Fine Motor — Baseline (Monitor): Week 52 (Monitor) | 0 | 0 |
| Fine Motor — Baseline (Monitor): Week 52 (Below) | 1 | 1 |
| Fine Motor — Baseline (Below): Week 52 (Above) | 0 | 0 |
| Fine Motor — Baseline (Below): Week 52 (Monitor) | 0 | 0 |
| Fine Motor — Baseline (Below): Week 52 (Below) | 1 | 1 |
| Gross Motor — Baseline (Above): Week 52 (Above) | 1 | 0 |
| Gross Motor — Baseline (Above): Week 52 (Monitor) | 0 | 0 |
| Gross Motor — Baseline (Above): Week 52 (Below) | 0 | 0 |
| Gross Motor — Baseline (Monitor): Week 52 (Above) | 0 | 0 |
| Gross Motor — Baseline (Monitor): Week 52 (Monitor) | 0 | 0 |
| Gross Motor — Baseline (Monitor): Week 52 (Below) | 0 | 0 |
| Gross Motor — Baseline (Below): Week 52 (Above) | 3 | 1 |
| Gross Motor — Baseline (Below): Week 52 (Monitor) | 0 | 2 |
| Gross Motor — Baseline (Below): Week 52 (Below) | 2 | 2 |
| Personal - Social — Baseline (Above): Week 52 (Above) | 3 | 2 |
| Personal - Social — Baseline (Above): Week 52 (Monitor) | 0 | 0 |
| Personal - Social — Baseline (Above): Week 52 (Below) | 0 | 0 |
| Personal - Social — Baseline (Monitor): Week 52 (Above) | 2 | 0 |
| Personal - Social — Baseline (Monitor): Week 52 (Monitor) | 0 | 0 |
| Personal - Social — Baseline (Monitor): Week 52 (Below) | 0 | 0 |
| Personal - Social — Baseline (Below): Week 52 (Above) | 1 | 1 |
| Personal - Social — Baseline (Below): Week 52 (Monitor) | 0 | 0 |
| Personal - Social — Baseline (Below): Week 52 (Below) | 0 | 2 |
| Problem Solving — Baseline (Above): Week 52 (Above) | 4 | 3 |
| Problem Solving — Baseline (Above): Week 52 (Monitor) | 0 | 0 |
| Problem Solving — Baseline (Above): Week 52 (Below) | 0 | 0 |
| Problem Solving — Baseline (Monitor): Week 52 (Above) | 0 | 0 |
| Problem Solving — Baseline (Monitor): Week 52 (Monitor) | 0 | 0 |
| Problem Solving — Baseline (Monitor): Week 52 (Below) | 0 | 0 |
| Problem Solving — Baseline (Below): Week 52 (Above) | 1 | 0 |
| Problem Solving — Baseline (Below): Week 52 (Monitor) | 1 | 0 |
| Problem Solving — Baseline (Below): Week 52 (Below) | 0 | 2 |
Change from baseline to Week 52 in body weight was reported.
| kilograms | Setmelanotide: PPL Group | Setmelanotide: BBS Group |
|---|---|---|
| Change From Baseline in Body Weight | -7.139 ± 5.0834 | -0.327 ± 2.9572 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE was defined as any AE that started or worsened in intensity on or after the date of the first administration of study drug.
| Participants | Setmelanotide: PPL Group | Setmelanotide: BBS Group |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 7 | 5 |
A TEAE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE was defined as any AE that started or worsened in intensity on or after the date of the first administration of study drug. TEAEs were graded according to Common Terminology Criteria for Adverse Events (CTCAE) criteria. Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life Threatening; Grade 5- Death related to AE.
| Participants | Setmelanotide: PPL Group | Setmelanotide: BBS Group |
|---|---|---|
| Mild | 2 | 5 |
| Moderate | 5 | 0 |
| Severe | 0 | 0 |
| Life Threatening | 0 | 0 |
| Death | 0 | 0 |
Collected over From first dose of study drug up to Week 56. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Setmelanotide: PPL Group | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Setmelanotide: BBS Group | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Event | Setmelanotide: PPL Group | Setmelanotide: BBS Group |
|---|---|---|
| Skin hyperpigmentationSkin and subcutaneous tissue disorders | 5/7 | 4/5 |
| NasopharyngitisInfections and infestations | 2/7 | 3/5 |
| Injection site bruisingGeneral disorders | 1/7 | 3/5 |
| Injection site pruritusGeneral disorders | 1/7 | 3/5 |
| VomitingGastrointestinal disorders | 4/7 | 3/5 |
| Upper respiratory tract infectionInfections and infestations | 4/7 | 0/5 |
| FallInjury, poisoning and procedural complications | 4/7 | 0/5 |
| Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/7 | 1/5 |
| InfluenzaInfections and infestations | 0/7 | 2/5 |
| PyrexiaGeneral disorders | 2/7 | 2/5 |
The safety analysis set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Setmelanotide: PPL Group | Setmelanotide: BBS Group | Total |
|---|---|---|---|
| Mean | 3.4 ± 0.53 | 3.8 ± 1.30 | 3.6 ± 0.90 |
| Sex: Female, Male(Participants) | Setmelanotide: PPL Group | Setmelanotide: BBS Group | Total |
|---|---|---|---|
| Female | 2 | 3 | 5 |
| Male | 5 | 2 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Setmelanotide: PPL Group | Setmelanotide: BBS Group | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 4 | 5 | 9 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Setmelanotide: PPL Group | Setmelanotide: BBS Group | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 |
| Race — Asian | 0 | 1 | 1 |
| Race — White | 3 | 4 | 7 |
| Race — Other | 2 | 0 | 2 |
| Race — Unknown or Not Reported | 2 | 0 | 2 |
| Body Mass Index (BMI) Z-score(z-score) | Setmelanotide: PPL Group | Setmelanotide: BBS Group | Total |
|---|---|---|---|
| Mean | 10.749 ± 3.8400 | 4.233 ± 1.0742 | 8.034 ± 4.4408 |
| BMI(kg/m^2) | Setmelanotide: PPL Group | Setmelanotide: BBS Group | Total |
|---|---|---|---|
| Mean | 34.347 ± 7.0673 | 23.716 ± 3.5184 | 29.918 ± 7.8559 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2022 to primary completion in Sep 2023, 18 months.
Results were first posted in Jul 2024, 9 months after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 18 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Setmelanotide
Rhythm Pharmaceuticals, Inc. →